ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC.
Options
BORIS DOI
PubMed ID
40582281
Date of Publication
2025-06-23
Publication Type
Article
Subject(s)
Language(s)
en
Contributor(s)
Dimopoulou, Georgia | |
van Schil, Paul | |
König, David | |
Mauti, Laetitia | |
Itchins, Malinda | |
Oselin, Kersti | |
Landi, Lorenza | |
Pérol, Maurice | |
Popat, Sanjay | |
Aigner, Clemens | |
Forde, Patrick | |
de Jong, Wouter K | |
Roschitzki-Voser, Heidi | |
Ruepp, Barbara | |
Solomon, Benjamin | |
Finn, Stephen | |
Dafni, Urania | |
Stahel, Rolf | |
Peters, Solange |
Additional Credits
Series
Lung Cancer
Publisher
Elsevier
ISSN
1872-8332
0169-5002
Access(Rights)
open.access